| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 74, 565-570, Copyright © 1992 by Endocrine Society
ARTICLES |
MC Batista, TP Cartledge, AW Zellmer, LK Nieman, GR Merriam and DL Loriaux
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892.
Serum concentrations of progesterone begin to rise just before the midcycle gonadotropin surge that leads to ovulation. To examine the role of progesterone in the regulation of these events, we evaluated the effects of a low dose (1 mg/day, orally) of the antiprogesterone RU 486 on the timing of the gonadotropin surge and ovulation in normally cycling women. The drug or a placebo was given for 5 or 15 days, starting when the dominant follicle reached 14-16 mm. RU 486 consistently delayed the timing of the midcycle gonadotropin surge and the subsequent collapse of the dominant follicle, despite rising estradiol concentrations and normal follicular development. Unexpectedly, RU 486 also delayed the emergence of the periovulatory progesterone rise. The addition of progesterone (5-10 mg/day, im, for 2 days) to a 5-day course of RU 486 after the emergence of a mature follicle readily induced LH and FSH surges and completely reversed the effects of RU 486 at midcycle. Our results suggest that RU 486 delays the midcycle gonadotropin surge and ovulation by suppressing or antagonizing an ovarian progestational signal. Progesterone may, thus, represent the ultimate ovarian signal to the estrogen-primed hypothalamic-pituitary unit to trigger the gonadotropin surge that leads to ovulation.
This article has been cited by other articles:
 |
|
 |
|
  I. E. Messinis Ovarian feedback, mechanism of action and possible clinical implications Hum. Reprod. Update, September 1, 2006; 12(5): 557 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A.R. Doi, M. Al-Zaid, P. A. Towers, C. J. Scott, and K. A.S. Al-Shoumer Irregular cycles and steroid hormones in polycystic ovary syndrome Hum. Reprod., September 1, 2005; 20(9): 2402 - 2408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. L. Escudero, P. J. Boerrigter, H. J. T. C. Bennink, R. Epifanio, J. A. Horcajadas, F. Olivennes, A. Pellicer, and C. Simon Mifepristone Is an Effective Oral Alternative for the Prevention of Premature Luteinizing Hormone Surges and/or Premature Luteinization in Women Undergoing Controlled Ovarian Hyperstimulation for in Vitro Fertilization J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2081 - 2088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Leminen, T. Raivio, S. Ranta, J. Oehler, H. von Hertzen, O. A Janne, and O. Heikinheimo Late follicular phase administration of mifepristone suppresses circulating leptin and FSH - mechanism(s) of action in emergency contraception? Eur. J. Endocrinol., March 1, 2005; 152(3): 411 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Gemzell-Danielsson and L. Marions Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraception Hum. Reprod. Update, July 1, 2004; 10(4): 341 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Curry Jr. and K. G. Osteen The Matrix Metalloproteinase System: Changes, Regulation, and Impact throughout the Ovarian and Uterine Reproductive Cycle Endocr. Rev., August 1, 2003; 24(4): 428 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Marions, K. Hultenby, I. Lindell, X. Sun, B. Stabi, and K. G. Danielsson Emergency Contraception With Mifepristone and Levonorgestrel: Mechanism of Action Obstet. Gynecol., July 1, 2002; 100(1): 65 - 71. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. De Geyter, M. De Geyter, P. R. Huber, E. Nieschlag, and W. Holzgreve Progesterone serum levels during the follicular phase of the menstrual cycle originate from the crosstalk between the ovaries and the adrenal cortex Hum. Reprod., April 1, 2002; 17(4): 933 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Brown, L. Cheng, S. Lin, and D. T. Baird Daily Low-Dose Mifepristone Has Contraceptive Potential by Suppressing Ovulation and Menstruation: A Double-Blind Randomized Control Trial of 2 and 5 mg per Day for 120 Days J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 63 - 70. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Stratton, B. Hartog, N. Hajizadeh, J. Piquion, D. Sutherland, M. Merino, Y. J. Lee, and L. K. Nieman A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women Hum. Reprod., May 1, 2000; 15(5): 1092 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Xiao, L. Xia-Zhang, D. Shanen, and M. Ferin Tonic Support of Luteinizing Hormone Secretion by Adrenal Progesterone in the Ovariectomized Monkey Replaced with Midfollicular Phase Levels of Estradiol J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2233 - 2238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Spitz and C.W. Bardin Mifepristone (RU 486) -- A Modulator of Progestin and Glucocorticoid Action N. Engl. J. Med., August 5, 1993; 329(6): 404 - 412. [Full Text]
|
|
|
|
|
|
D. T. Baird and A. F. Glasier Hormonal Contraception N. Engl. J. Med., May 27, 1993; 328(21): 1543 - 1549. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
